Mutual of America Capital Management LLC Sells 1,422 Shares of IDEXX Laboratories, Inc. $IDXX

Mutual of America Capital Management LLC lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 7.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 18,220 shares of the company’s stock after selling 1,422 shares during the period. Mutual of America Capital Management LLC’s holdings in IDEXX Laboratories were worth $11,641,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Blalock Williams LLC acquired a new stake in shares of IDEXX Laboratories during the 3rd quarter valued at about $590,000. Arkadios Wealth Advisors bought a new position in IDEXX Laboratories during the second quarter worth about $405,000. Orion Porfolio Solutions LLC boosted its holdings in IDEXX Laboratories by 116.6% during the second quarter. Orion Porfolio Solutions LLC now owns 10,718 shares of the company’s stock valued at $5,749,000 after purchasing an additional 5,770 shares in the last quarter. USA Financial Formulas bought a new stake in shares of IDEXX Laboratories in the 3rd quarter valued at approximately $2,381,000. Finally, Beacon Investment Advisory Services Inc. raised its holdings in shares of IDEXX Laboratories by 15.7% in the 3rd quarter. Beacon Investment Advisory Services Inc. now owns 56,241 shares of the company’s stock worth $35,932,000 after buying an additional 7,616 shares in the last quarter. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently commented on IDXX. Leerink Partners set a $785.00 price target on IDEXX Laboratories in a research note on Monday, November 3rd. BTIG Research boosted their target price on shares of IDEXX Laboratories from $785.00 to $830.00 and gave the company a “buy” rating in a research note on Tuesday, November 4th. Barclays assumed coverage on shares of IDEXX Laboratories in a research report on Monday, December 8th. They set an “overweight” rating and a $850.00 target price for the company. Stifel Nicolaus set a $775.00 price target on shares of IDEXX Laboratories in a research report on Monday, November 3rd. Finally, UBS Group raised their price objective on shares of IDEXX Laboratories from $710.00 to $750.00 and gave the stock a “neutral” rating in a report on Tuesday, November 4th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, IDEXX Laboratories presently has a consensus rating of “Moderate Buy” and an average price target of $763.50.

Insider Activity at IDEXX Laboratories

In other news, EVP Nimrata Hunt sold 9,425 shares of the business’s stock in a transaction on Friday, November 7th. The stock was sold at an average price of $703.34, for a total transaction of $6,628,979.50. Following the completion of the sale, the executive vice president owned 21,149 shares in the company, valued at $14,874,937.66. The trade was a 30.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.98% of the company’s stock.

IDEXX Laboratories Trading Up 0.6%

IDXX opened at $697.82 on Tuesday. IDEXX Laboratories, Inc. has a 1-year low of $356.14 and a 1-year high of $769.98. The stock has a market capitalization of $55.72 billion, a PE ratio of 55.34, a PEG ratio of 3.71 and a beta of 1.67. The company has a current ratio of 1.18, a quick ratio of 0.87 and a debt-to-equity ratio of 0.24. The firm has a 50-day moving average price of $706.41 and a two-hundred day moving average price of $657.44.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Monday, November 3rd. The company reported $3.22 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.14 by $0.08. The company had revenue of $1.11 billion for the quarter, compared to analyst estimates of $1.07 billion. IDEXX Laboratories had a net margin of 24.65% and a return on equity of 67.78%. IDEXX Laboratories’s quarterly revenue was up 13.3% on a year-over-year basis. During the same period in the prior year, the business earned $2.80 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.810-13.010 EPS. As a group, equities analysts anticipate that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current fiscal year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.